Picture EBD Group World of Partnering Opportunities 650x100px
Person › Details

Andrew Mielach (Tiberend Strategic Advisors (NY))

Mielach, Andrew (LifeSci 201404 at LifeSci Communications before Tiberend Strategic Advisors)


Organisation Organisation Tiberend Strategic Advisors (NY)
Products Product public relations / investor relations / marcom (services)

Cerevance. (4/14/20). "Press Release: Cerevance Closes $45 Million Series B Financing". Boston, MA.

Proceeds to Fund a Diverse Pipeline of Therapeutics Acting on Novel Targets for Brain Diseases

Cerevance, a private drug discovery and development company focused on brain diseases, has closed a Series B financing, bringing in $45 million from new investors including GV (formerly Google Ventures), Bill Gates and Foresite Capital, as well as all of the company’s previous investors, which include Takeda Ventures, Inc., the corporate venture arm of Takeda Pharmaceutical Company, Ltd., the Dementia Discovery Fund and Lightstone Ventures.

Cerevance will use the proceeds of the financing to continue identifying novel therapeutic targets for central nervous system diseases, such as Alzheimer’s disease, by transcriptionally and epigenetically profiling specific neuronal and glial cell populations in thousands of post-mortem human brain tissue samples and advancing a diverse portfolio of therapeutic programs against them.

“Cerevance has a differentiated approach to neurotherapeutics and continues to apply its powerful NETSseq platform to central nervous system diseases,” said David Schenkein, M.D., General Partner at GV. “With exceptional science, a strong sense of urgency and a leadership team that has previously succeeded together in drug discovery, Cerevance is well-positioned to deliver life-changing therapeutics for patients with brain diseases.”

“It’s hard to imagine a more stellar group of investors supporting us,” said Brad Margus, chief executive officer of Cerevance. “We look forward to drawing on their expertise in deep data analysis and therapeutic development as we mine our unique biological data sets to advance new, desperately needed therapies for brain diseases.”

About Cerevance

Cerevance, a private, clinical-stage pharmaceutical company focused on brain diseases, is applying a new technology, called NETSseq, to reveal transcriptional and epigenetic differences between specific cell types in mature human brains. NETSseq profiles neuronal and glial cell populations at depths not possible with other approaches, generating unprecedented data sets and insights. The company has thus far partnered with 14 brain banks around the world to assemble a growing collection of more than 7,000 clinically annotated, human brain tissue samples from healthy and diseased donors spanning nine decades in age. By applying NETSseq to specific cell types critical to circuits disrupted by disease and comparing vulnerable and resilient cell populations, Cerevance’s scientists have begun identifying targets and advancing a pipeline of novel therapeutics that modulate them for CNS diseases.

All trademarks used or mentioned in this release are protected by law.


Robert Middlebrook, +1-408-220-5722

Andrew Mielach,, +1- 646-876-5868

Record changed: 2023-03-06


Picture Berlin Partner Special Topic HealthCapital Berlin-Brandenburg 650x200px

More documents for Andrew Mielach

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Biotech Showcase 2024 San Francisco 650x300px

» top